Severe Radiological Manifestation in Patients with Diabetes and Pulmonary Tuberculosis: A Cross-sectional Study

Peize Zhang

The Third People's Hospital of Shenzhen

Juan Xiong

Shenzhen University

Shenlin Zhan

The Third People's Hospital of Shenzhen

Tantan Ren

The Third People's Hospital of Shenzhen

Yuxiang Wang

The Third People's Hospital of Shenzhen

Liang Fu

The Third People's Hospital of Shenzhen

Guofang Deng (✉ jxxk1035@yeah.net)

The Third People's Hospital of Shenzhen

Research Article

Keywords: Diabetes mellitus, HbA1C, Tuberculosis, Lung cavity, Radiography, lung infiltration, Chest CT

Posted Date: August 26th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-812242/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose: Diabetes mellitus (DM) is believed to affect tuberculosis (TB) at multiple levels in disease control and treatment efficacy, but clinical and radiological presentation resulting from interaction of the two diseases is not known. We conducted a retrospective study to investigate how glycemic control impacts radiological and clinical manifestations in TB patients.

Methods: A cross-sectional study was conducted on data obtained from medical records of 438 patients confirmed with TB-DM comorbidity at The Third people's hospital of Shenzhen from April 1, 2014 to April 30, 2019. Their CT images were reviewed, and patients were divided into subgroups according to lung cavitation: with and without cavities, and number of segments showing pulmonary infiltration: <4 segment, 4-8 segment, >8 segment infiltrates. We then compared clinical parameters between these groups.

Results: The median age of the patients was 50.0 years (IQR 43.3-56) and 86% (n=375) of them were male. Pulmonary cavities were found in 80.8% patients. 42.7% and 27.2% patients were seen to have infiltration involving 4-8 and >8 lung segments respectively. Patients presented with cavitation and infiltration involving a greater number of lung segments had significantly higher values of WBC, MONO%, GRA%, CRP, lower LYN% level and higher bacterial burden in sputum ($P<0.001$). Higher HbA1c and FBG were only observed in patients with lung cavities ($P<0.001$). There was no difference in positive ELISPOT.TB and PCT level between the groups regardless of presence or absence of lung cavity ($P>0.9$ and $P=0.1$ respectively). Lower HGB, ALB and higher PCT were observed in patients with infiltration involving more lung segments.

Conclusion: Hyper-inflammation in peripheral blood was significantly associated with cavity and the number of lung lesions. Hyperglycemia was significantly associated with the development of lung cavity. Glycemic control and inflammation influenced radiographic manifestations in patients with TB-DM.

Introduction

Diabetes mellitus (DM) and Tuberculosis (TB) are converging health conditions and represents an immense public health concern across the globe. DM has been reported to be a known risk factor for TB and complicates disease management and control [1]. DM is also believed to affect clinical and radiological manifestations of pulmonary tuberculosis. It has been demonstrated in numerous studies that co-existing DM and TB conditions may induce an increased frequency of pulmonary atypical manifestation, including lower lobe lung opacity, occurrence of more lung lesions, cavity and extensive parenchymal involvement. Moreover, it was indicated that radiological manifestations are potentially correlated with glycemic control in DM[2–4]. Cavitation is a rather severe event of pulmonary tuberculosis and is mostly associated with an increased risk of disease transmission and poor treatment outcomes, including delayed sputum culture conversion, relapse, development of drug resistance[5]. In some cases, cavitation and multi-lobe infiltration leads to pulmonary structural damage and vascular compromise,

including chronic aspergillosis, bronchiectasis and recurrent hemoptysis[6]. In this study, we analyzed laboratory results and thoracic CT findings recorded at the time diagnosis was confirmed from patients with co-existing DM and PTB to find out related factors associated with severe pulmonary manifestation.

Methods

Study design and participants

We conducted a cross-sectional study to explore the relationship between pulmonary CT scan features and clinical characteristics. We reviewed 1106 patients diagnosed of DM and TB at the Third People's Hospital of Shenzhen from April 1, 2014 to April 30, 2019. Diabetes and active pulmonary tuberculosis are defined according to the WHO diagnostic criteria launched between 1999–2013 [7, 8]. The inclusion criteria of this study are (1) age ≥ 18 years, (2) newly confirmed diagnosis of DM-PTB followed national standard, (3) patients who were not already on anti-TB treatment or had started regime in no more than 3 days prior to enrollment, (4) chest CT performed in our hospital and complete results recorded. The exclusion criteria are (1) HIV co-infection, corticosteroid / cytotoxic drugs taken within 3 months before disease onset, (2) pulmonary tuberculosis relapse, (3) No pulmonary CT scans taken at diagnosis confirmation. Reason for excluding patients with HIV and immune compromised conditions is that impaired immune states has been shown to impact the CT image performance [9]. Patients with previous tuberculosis were excluded as pulmonary structural damage could remain and lead to misjudgment of CT manifestation. Finally, 438 patients were enrolled in this study.

Data Collection

Demographic, clinical and laboratory data were obtained from medical records for all eligible patients. The information recorded included patient demographics, medical history, underlying comorbidities, laboratory findings and glycemic control status. Laboratory findings included white blood cell count, neutrophil, lymphocyte, c-reactive protein, procalcitonin, hemoglobin, and serum albumin. Glycemic control status included FBG (free blood glucose) and the level of HbA1c (Hemoglobin A1C) when diagnosis was confirmed.

Patients with suspected pulmonary tuberculosis were sent for chest thin-section computed tomographic (CT) scan at administration. The CT scanners used in our study included GE Revolution CT256, CT64 from United Imaging and LightSpeed 16 from GE. The scanning protocols were as follows: tube voltage, 120 kV; automatic tube current (180–400 mA); iterative reconstruction; 64 mm detector; rotation time, 0.35 s; slice thickness, 1 mm; collimation, 0.625 mm; pitch, 1.5; matrix, 512×512 ; and breath hold at full inspiration. Reconstruction kernel used was lung smooth with a thickness of 1 mm and an interval of 0.8 mm. Lung windows with window width 1200 HU and window level-600 HU were used for image reading.

All patients' CT images were reviewed by a trained team of physicians and radiologists at The Third People's Hospital of Shenzhen. Chest CT scans were examined on the occurrence and number of lung cavity (cavity diameter ≥ 5 mm, cavity wall ≥ 1 mm,) and lobes showing pulmonary infiltration. Cavity

and lung infiltrates are defined according to the Fleischner glossary for thoracic imaging[10]. The 438 eligible patients were categorized into cavity and non-cavity group based on lung cavitation status. Based on the number of segments showing lung infiltration, we also stratified these patients into three clinically distinctive subgroups: <4 segment infiltration, 4–8 segment infiltration and > 8 segment infiltration. We then compared clinical characteristics variations across these subgroups.

Statistical Analyses

All statistical analyses were performed by the R software program (version 4.1.0; R Project for Statistical Computing, Vienna, Austria). Descriptive statistics were calculated for each variable. All continuous variables were examined for normality by Shapiro-Wilk test. We present all continuous variables as median and interquartile range (IQR). Categorical variables were expressed as percentage and frequency. Wilcoxon rank sum or Kruskal-Wallis test was used to compare continuous variables among different groups. Chi-squared tests of independence were used to explore the relationship between the subgroups and categorical variables. *P*-value < 0.05 was considered statistically significant, and all reported *P*-values were two-sided.

Results

Baseline demographic and clinical characteristics of the 438 patients included in the study are presented in Table1. The median age was 50.0 years (IQR 43.3-56) and 86% (n=375) of them were male. 11.6% were HBV-coinfected, 17.1% had cardiac diseases and 1.1% were on dialysis. More than 80% patients had microbial results and glycemic results. 86.8% patients had ELISPOT.TB (enzyme-linked immune-spot assay. Tuberculosis) assay. Chest CT Imaging revealed lung cavities in 80.8% patients. 42.7% patients exhibited infiltration involving 4-8 lung segments. Comparison of clinical parameters based on cavitation status (Table 2) revealed a significant gender difference between patients with and without lung cavity (*P*=0.006). Proportion of sputum smear, DNA and culture positive patients were significantly higher in the cavity group than non-cavity group (*P*<0.001). Patients with cavity were also noted to have significantly higher values of WBC, MONO%, GRA%, HbA1c, FBG and CRP. Intriguingly, the cavity group had lower LYN level. No significant differences was observed between the two groups in age, ELISPOT.TB, HGB and ALB.

Table1

Sociodemographic and clinical characteristics of the participants

Characteristics	N(%)
Gender	
Male	375 (86.0)
Female	63 (14.0)
Age (year)	50.0 (IQR 43.3-56)
Comorbidity	
HBV-coinfection	51 (11.6)
Cardiac disease	75 (17.1)
Dialysis	5 (1.1)
CRP	399 (91.1)
PCT	343 (78.3)
ELISPOT.TB	376 (86.8)
Microbiology	
Smear	392 (89.5)
TB-DNA	358 (81.7)
Culture	385 (87.9)
Glycemic index	
FBG	409(93.4)
Hb1AC	370(84.5)

Abbreviations: CRP: C-reactive protein; PCT: procalcitonin; ELISPOT.TB: enzyme-linked immune-spot assay. Tuberculosis; FBG: free blood glucose; HbA₁C: Hemoglobin A1C;

Table 2

Characteristics of participants stratified by presence or absence of lung cavity

Characteristic	Overall, N = 438 n/N	Non-cavity, N = 84 n/N	Cavity, N = 354 n/N	p-value
Gender (male)	375/438 (86%)	64/84 (76%)	311/354 (88%)	0.006
Age (year)	50.0 (43.3,56.0)	51.0 (44.0,58.0)	50.0 (43.0,55.0)	0.200
ELISPOT.TB	290/376 (77%)	52/67 (78%)	238/309 (77%)	>0.9
Sp. smear	253/392 (65%)	31/75 (41%)	222/317 (70%)	<0.001
Sp. TB-DNA	277/358 (77%)	37/69 (54%)	240/289 (83%)	<0.001
Sp. culture	311/385 (81%)	46/74 (62%)	265/311 (85%)	<0.001
WBC	7.7 (6.3,9.6)	7.2 (5.7,8.6)	7.8 (6.4,9.7)	0.012
GRA%	69.9 (62.2,77.5)	67.2 (59.6,75.5)	70.0 (63.1,77.9)	0.045
LYN%	18.6 (13.0,25.2)	20.8 (14.9,29.3)	18.3 (12.6,24.1)	0.007
MONO%	8.7 (6.5,10.7)	7.3 (5.9,9.5)	8.9 (6.7,10.9)	0.004
HGB	131.0 (115.0,142.0)	131.5 (109.8,142.0)	131.0 (116.0,142.0)	0.500
ALB	38.8 (34.8,41.8)	40.0 (36.1,42.4)	38.5 (34.6,41.7)	0.140
HbA1c	10.7 (8.4,12.6)	9.3 (6.9,11.4)	10.9 (8.7,12.8)	<0.001
FBG	9.7 (7.07,13.1)	7.5 (6.20,10.1)	10.2 (7.50,13.3)	<0.001
CRP	38.3 (11.5,81.7)	12.9 (4.9,36.0)	46.5 (15.3,86.5)	<0.001
PCT	0.1 (0.035,0.1)	0.0 (0.028,0.1)	0.1 (0.037,0.1)	0.100

Abbreviations: ELISPOT.TB: enzyme-linked immune-spot assay. Tuberculosis; sp.: sputum; WBC: white blood cell; GRA%: neutrophil ratio. LYN%: Lymphocyte ratio; MONO%: Monocyte ratio; HGB: Hemoglobin; ALB: Albumin; HbA1C: Hemoglobin A1C; FBG: free blood glucose; CRP: C-reactive protein; PCT: procalcitonin

In addition to the above comparison, patients were also divided into 3 subgroups according to the number of lung segments involving infiltration: <4 segment (n=132), >=4 and <=8 segment (n=187), and >8 segment (n=119). The severity of disease was shown to be positively related to the number of segments involved. The difference in patients' characteristic amongst the three subgroups were summarized in Table 3. There was significant difference amongst three subgroups in bacterial positivity, WBC, GRA, LYN, MONO, HGB, CRP, PCT and ALB. Patients with more segment involvement tend to have higher value of WBC, GRA, CRP and PCT, lower level of LYN, HGB and ALB. However, there were no significant differences amongst the three subgroups for HbA1c and FBG.

Table 3

Characteristics of participants stratified by number of lung segments showing infiltrates

Characteristic	<4 seg., N = 132 n/N	4-8 seg., N = 187 n/N	>8 seg., N = 119 n/N	<i>p</i> -value
Gender (male)	116/132 (88%)	156/187 (83%)	103/119 (87%)	0.500
Age	49.0 (43.0,54.2)	51.0 (44.5,56.0)	49.0 (43.0,56.0)	0.300
ELISPOT.TB	82/108 (76%)	136/164 (83%)	72/104 (69%)	0.032
Sp. smear	55/117 (47%)	122/173 (71%)	76/102 (75%)	<0.001
Sp. TB-DNA	62/103 (60%)	137/160 (86%)	78/95 (82%)	<0.001
Sp. culture	79/112 (71%)	142/169 (84%)	90/104 (87%)	0.004
WBC	7.2 (6.1,8.5)	7.8 (6.2,9.7)	8.1 (6.8,10.4)	0.004
GRA%	65.3 (59.6,71.2)	69.9 (63.1,77.8)	74.0 (67.4,80.8)	<0.001
LYN%	22.9 (18.5,29.2)	17.5 (12.6,24.4)	15.0 (10.3,20.6)	<0.001
MONO%	8.1 (6.2,10.1)	9.2 (6.9,11.7)	8.6 (6.5,10.2)	0.012
HGB	137.5 (126.0,148.2)	129.0 (113.5,140.0)	125.0 (108.0,135.5)	<0.001
ALB	40.6 (38.0,42.9)	38.4 (34.6,41.7)	36.2 (32.1,40.0)	<0.001
HbA1c	10.5 (8.5,11.9)	10.6 (8.3,12.8)	11.4 (8.4,13.2)	0.150
FBG	9.5 (7.4,12.2)	9.4 (6.7,13.1)	10.3 (7.0,13.6)	0.500
CRP	12.5 (4.3,33.1)	43.3 (16.9,85.9)	63.5 (34.2,94.8)	<0.001
PCT	0.0 (0.03,0.1)	0.1 (0.04,0.1)	0.1 (0.05,0.2)	<0.001

Abbreviations: ELISPOT.TB: enzyme-linked immune-spot assay. Tuberculosis; sp.: sputum; WBC: white blood cell; GRA%: neutrophil ratio; LYN%: Lymphocyte ratio; MONO%: Monocyte ratio; HGB: Hemoglobulin; ALB: Albumin; HbA1C: Hemoglobin A1C; FBG: free blood glucose; CRP: C-reactive protein; PCT: procalcitonin.

Discussion

The dual disease burden of tuberculosis and diabetes (DM-TB) poses substantial challenges to diagnosis and treatment approach. Hyperglycemia is shown to be associated with severe tuberculosis, delayed culture conversion and poor prognosis. How diabetes impact pulmonary radiological manifestations of patients with tuberculosis is still unclear.

Previous studies demonstrated that hyperglycemia increased the risk of pulmonary TB incidence and was strongly associated with worsen pulmonary radiographic manifestation in TB patients[11]. TB patients with hyperglycemia presented with cavities and alveolar infiltrates more frequently than those with

normoglycemia [12, 13]. Patients with uncontrolled diabetics with HbA1c > 9% were more likely to exhibit an increased number of cavity in lower lung field and more lobe involvement on chest CT[12]. HbA1c and FBG are often taken as indexes for glycemia control. Our findings indicated that multiple pulmonary cavities were often associated with changes in these two indexes. We also indicated that severe radiographic manifestations were associated with a systemic hyper-inflammation state characterized by elevation of WBC counts, neutrophil, monocyte, CRP and decreased lymphocyte in serum. Impaired innate immune responses had been described in many studies for patients with diabetes[14, 15]. Hyperglycemia combined with oxidative stress induce higher cytokines IL-17A, IL-8, and IL-10 in the lung which contributes to an exacerbated proinflammatory response[16, 17]. Some other components of innate immunity such as the function of neutrophils, macrophages, DC, NK cells are drastically compromised in individuals with DM which leads to delayed antigen presentation and impaired microbicidal activity [15, 18]. Persistent inflammation has been observed during anti-TB treatment in patients with diabetes [19]. We then inferred that over-expression of cytokines, such as CRP in TB-DM patients were associated with escalating neutrophil recruitment and infiltration, which led to more inflammation and necrosis, and then potentially resulted in cavity formation.

Another mechanism contributing to the severe inflammation is adaptive immune dysfunction. Impaired T helper 1 cell lowers production of IFN γ , which weakens the killing activity of macrophages and leads to failing control of mycobacterium growth[14]. High bacterial load and over inflammation in turn gives rise to development of more extensive lung lesions, cavitation and infiltration extending to more lobes[20]. Of note, our findings also indicated that decreased serum lymphocyte was linked to severe radiographic presentation of pulmonary TB, which also suggested that a compromised adaptive immune system might play an important role in the onset of active TB in patients with diabetes [21].

In addition, we noted from the findings that the level of HGB and ALB were lower in patients with multi-fragment infiltration. Individuals with malnutrition have been reported to be associated with severe pulmonary manifestation[22]. We believed that lower HGB and ALB in serum are indicative biomarkers of malnutrition and severe disease. It is also noteworthy that PCT level is seen to increase slightly in patients with more lung infiltration. PCT used to be taken as a robust biomarker for bacterial infection and sepsis[23]. It has been used to differentiate pulmonary tuberculosis from other pulmonary infections[24]. We thus speculated that bacterial co-infection should be noticed in patients with diffuse lung infiltration. Previous studies showed increased mycobacterial loads and higher proportions of smear positivity in hyperglycemic patients[3, 25, 26], our findings were in agreement and demonstrated that positive microbial results were frequently found in DM patients with pulmonary cavity and severe segment infiltration. The more severe the radiological manifestations, the heavier the bacterial burden.

There are some limitations in our study. Firstly, causal relationship between diabetes and severe radiological manifestation could not be set up according to our cross-sectional study design. Secondly, discrepancies driven by age, from symptom onset to diagnosis, clinical presentation and even other immune compromised factors were not stratified and further analyzed. Nevertheless, this internal

analysis demonstrated an association between glycemic status, hyper-inflammation and the presentation of pulmonary lesions in TB-DM comorbidities.

Conclusion

In summary, our findings revealed that severe radiological presentation in pulmonary TB patients with diabetes is associated with both hyperglycemia and a systemic pro-inflammatory state, which is characterized by elevation in the level of WBC counts, neutrophil and serum CRP and a lowered lymphocyte level. Strict glycemic control and inflammation alleviation might play a role in lung protection.

Declarations

Acknowledgments

The authors are grateful for the continued academic support from The National Clinical Research Center for Infectious Disease in China and Clinical Research Center for Infectious Diseases(tuberculosis) of Guangdong Province.

Authors' contributions

GD designed the study. PZ and SZ wrote the manuscript. TR, YW and LF contributed to data collection. JX interpreted the results and prepared Tables 1-3. All authors read and approved the final manuscript.

Funding

This study was funded by the Technology Project of Guangdong Province (2020B1111170014) and Tuberculosis Project of National Clinical Research Center (G2021010) which are government fund for the research of tuberculosis treatment and control. Juan Xiong was supported by SZU Top Ranking Project (86000000210).

Availability of data and materials

All original data used in the study has been de-identified and are available online from the corresponding author by request.

Ethics approval and consent to participate

The Ethical Committee of The Third People's Hospital approved the study and stated that patient consent was not necessary for this retrospective study. The director/administer of The Third People's Hospital granted us permission to access the medical records. The data used in this study was anonymized before its use.

Consent for publication

No applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. *Lancet Infect Dis* 2018, **18**(12):1329–1349.
2. Huang LK, Wang HH, Lai YC, Chang SC: **The impact of glycemic status on radiological manifestations of pulmonary tuberculosis in diabetic patients.** *PLoS One* 2017, **12**(6):e0179750.
3. Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N, Howards PP, Narayan KM, Blumberg HM: **Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia.** *Int J Tuberc Lung Dis* 2015, **19**(6):685–692.
4. Chiang CY, Lee JJ, Chien ST, Enarson DA, Chang YC, Chen YT, Hu TY, Lin CB, Suk CW, Tao JM *et al*: **Glycemic control and radiographic manifestations of tuberculosis in diabetic patients.** *PLoS One* 2014, **9**(4):e93397.
5. Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, Jain SK, Bishai WR: **Cavitary tuberculosis: the gateway of disease transmission.** *Lancet Infect Dis* 2020, **20**(6):e117-e128.
6. Shah M, Reed C: **Complications of tuberculosis.** *Curr Opin Infect Dis* 2014, **27**(5):403–410.
7. [https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-\(hba1c\)-in-diagnosis-of-diabetes-mellitus](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(hba1c)-in-diagnosis-of-diabetes-mellitus).
8. <https://apps.who.int/iris/handle/10665/44165>.
9. Han S, Yoon SH, Goo JM, Yim JJ: **Radiological features and progression of incipient active pulmonary tuberculosis according to risk factors.** *Int J Tuberc Lung Dis* 2019, **23**(6):698–706.
10. <https://thoracickey.com/fleischner-society-glossary-of-terms-for-thoracic-imaging/>.
11. Viney K, Mills T, Harley D: **Tuberculosis and diabetes mellitus: a dose-response relationship between the odds of tuberculosis and HbA1c.** *Int J Tuberc Lung Dis* 2019, **23**(10):1055–1059.
12. Zafar MI, Chen LL, Xiaofeng Y, Gao F: **Impact of Diabetes Mellitus on Radiological Presentation of Pulmonary Tuberculosis in Otherwise Non-Immunocompromised Patients: A Systematic Review.** *Curr*

13. Barreda NN, Arriaga MB, Aliaga JG, Lopez K, Sanabria OM, Carmo TA, Fróes Neto JF, Lecca L, Andrade BB, Calderon RI: **Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia.** *BMC Infect Dis* 2020, **20**(1):139.
14. Ayelign B, Negash M, Genetu M, Wondmagegn T, Shibabaw T: **Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis.** *J Immunol Res* 2019, **2019**:6196532.
15. Kumar Nathella P, Babu S: **Influence of diabetes mellitus on immunity to human tuberculosis.** *Immunology* 2017, **152**(1):13–24.
16. Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M, Orme IM, Ordway DJ, Basaraba RJ: **Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity.** *Am J Pathol* 2014, **184**(4):1104–1118.
17. Yew WW, Leung CC, Zhang Y: **Oxidative stress and TB outcomes in patients with diabetes mellitus?** *J Antimicrob Chemother* 2017, **72**(6):1552–1555.
18. Martinez N, Kornfeld H: **Diabetes and immunity to tuberculosis.** *Eur J Immunol* 2014, **44**(3):617–626.
19. Kumar NP, Fukutani KF, Shruthi BS, Alves T, Silveira-Mattos PS, Rocha MS, West K, Natarajan M, Viswanathan V, Babu S *et al*: **Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity.** *Elife* 2019, **8**.
20. Orme IM, Robinson RT, Cooper AM: **The balance between protective and pathogenic immune responses in the TB-infected lung.** *Nat Immunol* 2015, **16**(1):57–63.
21. Li K, Ran R, Jiang Z, Fan C, Li T, Yin Z: **Changes in T-lymphocyte subsets and risk factors in human immunodeficiency virus-negative patients with active tuberculosis.** *Infection* 2020, **48**(4):585–595.
22. Hoyt KJ, Sarkar S, White L, Joseph NM, Salgame P, Lakshminarayanan S, Muthaiah M, Vinod Kumar S, Ellner JJ, Roy G *et al*: **Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis.** *PLoS One* 2019, **14**(3):e0214011.
23. Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, Ryder S, Stirk L, Severens J, Kleijnen J: **Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.** *Health Technol Assess* 2015, **19**(96):v-xxv, 1–236.
24. Huang SL, Lee HC, Yu CW, Chen HC, Wang CC, Wu JY, Lee CC: **Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis.** *Int J Tuberc Lung Dis* 2014, **18**(4):470–477.
25. Park SW, Shin JW, Kim JY, Park IW, Choi BW, Choi JC, Kim YS: **The effect of diabetic control status on the clinical features of pulmonary tuberculosis.** *Eur J Clin Microbiol Infect Dis* 2012, **31**(7):1305–1310.
26. Hongguang C, Min L, Shiwen J, Fanghui G, Shaoping H, Tiejie G, Na L, Zhiguo Z: **Impact of diabetes on clinical presentation and treatment outcome of pulmonary tuberculosis in Beijing.** *Epidemiol Infect* 2015, **143**(1):150–156.